Welcome!

News Feed Item

Trimel Provides Corporate Update and Second Quarter 2014 Financial Results

- Natesto(TM) Receives FDA Approval

TORONTO, ONTARIO -- (Marketwired) -- 07/30/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.

Corporate Highlights

Natesto™ Approval

On May 28, 2014, the United States Food and Drug Administration approved Natesto™ (testosterone nasal gel), for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism).

Tefina™ Phase II Results

Also on May 28, 2014, Trimel announced positive top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder ("FOD"). Women treated with Tefina™ 0.6 mg reported a 35% increase in the average number of orgasms versus placebo (p=0.0013) and 58% of women had at least one orgasm, compared to 43% of women in the placebo group. Tefina™ 0.6 mg also showed a statistically significant (p=0.017) improvement in distress over placebo.

Estrace® Acquisition

On July 16, 2014, the Company announced that it has acquired from Shire plc the Canadian rights for Estrace® (17-beta estradiol), a product indicated for the treatment of symptomatic relief of menopausal symptoms. Estrace® has been available on the Canadian market for 39 years and generated revenues of USD$9.9 million in 2013 within a hormone replacement therapy ("HRT") market valued at USD$100 million and grew by 6% in 2013. It is anticipated that Estrace® will contribute significantly to the Company's earnings before interest, tax, depreciation, and amortization ("EBITDA") and future cash flows.

Private Placement

On July 30, 2014 the Company completed a private placement of 28,801,000 common shares of the Company at a price of CDN$0.62 per share for gross proceeds of CDN$17,856,620.

The Company has used the full net proceeds from the private placement to repay a significant portion of a convertible promissory note previously issued to First Generation Capital Inc. ("First Generation"), a company affiliated with Mr. Ian Ihnatowycz, the Chairman of the Board of Directors of the Company. Following this repayment, First Generation has advised that it intends to convert a portion of the note into a total of 8,945,796 common shares after August 21, 2014. Following such conversion, First Generation would hold approximately 23.7% of the company's common shares, thereby maintaining its current securityholding percentage. The indebtedness remaining under the note (expected to equal approximately US$4.1 million) following such conversion and repayment would remain outstanding in accordance with the terms of the note and no longer be convertible into common shares after such time.

As a result of the transactions noted above, the Company has received an additional USD$5.0 million from its senior secured lender pursuant to the terms and conditions of its applicable senior credit facility.

Financial Results for the Three Months Ended June 30, 2014 (All values in U.S. dollars)

Research and Development ("R&D") expenses were $4.1 million and $6.9 million respectively for the three months ended June 30, 2014 and 2013. The variance is primarily due to costs related to the filing of the Natesto™ new drug application ("NDA") that were incurred during the 2013 period. The decrease in Natesto™ related expenses is offset by higher Tefina™ clinical trial costs in 2014 as this study progressed to its completion during the quarter.

Trimel incurred General and Administrative ("G&A") expenses of $1.5 million and $2.4 million respectively for the three months ended June 30, 2014 and 2013. The decrease in spending was primarily attributable to lower salaries, benefits and share-based compensation, and lower legal fees related to arbitration, corporate and intellectual property matters. The arbitration matters were settled pursuant to a December 21, 2013 agreement.

For the three months ended June 30, 2014, the Company incurred a net loss of $0.05 per share as compared to a net loss of $0.07 per share for the same 2013 period.

At June 30, 2014, the Company had total assets of $22.4 million, as compared to $28.1 million at December 31, 2013 and total liabilities of $9.0 million at June 30, 2014, as compared to $14.5 million at December 31, 2013. The $5.8 million decrease in assets is primarily due to the $5.8 million decrease in cash during the period as it was used to fund current activities. The $5.6 million decrease in total liabilities was primarily impacted by $4.25 million milestone obligation paid to M&P Patent AG and payments related to the Company's debt facility, offset by a $2.5 million Natesto™ milestone accrual that was made in the second quarter of 2014.

The Company had a net cash outflow of $5.2 million for the three months ended June 30, 2014 and had $12.3 million of cash at June 30, 2014. The Company's average monthly burn rate during the three months ended June 30, 2014 was approximately US$1.7 million as compared to approximately $3.1 million for the three months ended June 30, 2013 after excluding certain payments made during the second quarter of 2013 (NDA filing fee for Natesto™, a milestone payment made to a technology partner and an inventory prepayment). The Company believes it has sufficient resources to fund its ongoing activities into 2015, depending on the timing of further clinical activities and barring unforeseen events. The Company's average monthly burn rate is a non-GAAP financial measure with no standard meaning under IFRS, which management uses to further evaluate the Company's results of operations in each reporting period.

The information set out above is in summary form. Readers are encouraged to review the Company's annual information form, financial statements (and accompanying notes), together with management's discussion and analysis available on SEDAR at www.sedar.com and on the Company's website at www.trimelpharmaceuticals.com.

Conference Call Details

Shareholders are reminded of the conference call to discuss the Company's second quarter results to be held on July 31, 2014 at 8:30 a.m. (Toronto time). To access the call live, please dial 416-340-2216 or 1-866-223-7781. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 7:00 p.m. (Toronto time) on Wednesday, August 6, 2014 by dialling 905-694-9451 or 1-800-408-3053, using access code: 8161397#.

About Trimel

Trimel is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health, and respiratory medicine. Natesto™, a product utilizing Trimel's licensed nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.

Notice regarding forward-looking statements:

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the performance of Estrace®, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 5, 2014 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.


                     TRIMEL PHARMACEUTICALS CORPORATION
       CONDENSED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION
                            AS AT JUNE 30, 2014
                                 UNAUDITED
                        (expressed in U.S. Dollars)

                                   ASSETS
                                                    June 30,   December 31,
                                                        2014           2013
                                              ------------------------------

CURRENT
  Cash                                          $ 12,289,692   $ 18,111,145
  Restricted cash                                     23,417         23,505
  Inventory                                        3,758,254      1,913,772
  Prepaids and other assets                          700,779      1,582,924
  Assets classified as held for sale                 107,135              -
                                              ------------------------------
                                                  16,879,277     21,631,346

NON-CURRENT ASSETS
  Property and equipment, net                      2,407,046      3,273,196
  Intangible assets                                3,068,900      3,216,800
                                              ------------------------------
TOTAL ASSETS                                    $ 22,355,223   $ 28,121,342
                                              ------------------------------


                                LIABILITIES

CURRENT
  Accounts payable and accrued liabilities       $ 5,678,088    $ 9,864,079
  Current portion of long-term debt, net of
   issuance costs                                  2,874,046      2,834,639
                                              ------------------------------
                                                   8,552,134     12,698,718

LONG-TERM
  Long-term debt, net of issuance costs              349,999      1,827,082
  Derivative financial instrument                     49,008         20,977
                                              ------------------------------
TOTAL LIABILITIES                                $ 8,951,141   $ 14,546,777
                                              ------------------------------


                            SHAREHOLDERS' EQUITY

Share capital                                    129,211,443    119,741,040
Warrants                                           1,039,705      1,039,705
Contributed surplus                                8,284,868      7,987,237
Accumulated other comprehensive (loss)            (1,539,663)    (1,639,862)
Deficit                                         (123,592,271)  (113,553,555)
                                              ------------------------------
TOTAL SHAREHOLDERS' EQUITY                        13,404,082     13,574,565
                                              ------------------------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY      $ 22,355,223   $ 28,121,342
                                              ------------------------------


                     TRIMEL PHARMACEUTICALS CORPORATION
  CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
         FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 AND 2013
                                 UNAUDITED
                        (expressed in U.S. Dollars)

                     For the three months ended   For the six months ended
                              June 30,                    June 30,
                             2014          2013          2014          2013
                    --------------------------------------------------------
EXPENSES
  Research and
   development        $ 4,139,357   $ 6,917,920   $ 6,849,318  $ 11,792,337
  General and
   administrative       1,531,071     2,361,902     2,806,136     5,764,213
                    --------------------------------------------------------
  Total operating
   expenses             5,670,428     9,279,822     9,655,454    17,556,550
                    --------------------------------------------------------

FINANCE COSTS, NET
  Interest on long-
   term debt and
   other financing
   costs                  179,786       369,723       356,498       658,378
  Interest income         (29,514)      (36,940)      (49,157)      (41,083)
  Foreign exchange
   (gain)/ loss         1,632,069      (471,406)       48,002      (468,036)
  Change in fair
   value of
   derivative
   financial
   instrument               7,220       (10,947)       27,919      (146,914)
                    --------------------------------------------------------
                        1,789,561      (149,570)      383,262         2,345
                    --------------------------------------------------------
TOTAL EXPENSES          7,459,989     9,130,252    10,038,716    17,558,895
                    --------------------------------------------------------
NET LOSS             $ (7,459,989) $ (9,130,252) $(10,038,716) $(17,558,895)
                    --------------------------------------------------------
                    --------------------------------------------------------

OTHER COMPREHENSIVE INCOME
(LOSS), NET OF INCOME TAX
Items that may be
 reclassified
 subsequently to
 profit or loss:
  Foreign currency
   translation
   adjustment           1,906,275    (1,403,787)      100,199    (1,530,274)
                    --------------------------------------------------------
TOTAL COMPREHENSIVE
 LOSS FOR THE PERIOD $ (5,553,714) $(10,534,039) $ (9,938,517) $(19,089,169)
                    --------------------------------------------------------
                    --------------------------------------------------------
Basic and diluted
 weighted average
 shares outstanding   163,126,438   132,555,004   158,947,911   112,108,917

Basic and diluted
 net loss per common
 share                    $ (0.05)      $ (0.07)      $ (0.06)      $ (0.16)


                     TRIMEL PHARMACEUTICALS CORPORATION
 CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
               FOR THE SIX MONTHS ENDED JUNE 30, 2014 AND 2013
                                  UNAUDITED
                         (expressed in U.S. Dollars)

                                                                Contributed
                          Notes Share capital       Warrants        surplus
                               ---------------------------------------------

Balance, January 1, 2013         $ 78,214,661    $ 3,452,607    $ 4,318,927

Net loss for the period                     -              -              -

Cumulative translation
 adjustment                                 -              -              -

----------------------------------------------------------------------------

Total comprehensive loss
 for the period                             -              -              -

Common shares, net of
 share issuance costs              41,526,379              -              -

Share based compensation                    -              -      1,000,556
----------------------------------------------------------------------------
Balance as at June 30,
 2013                           $ 119,741,040    $ 3,452,607    $ 5,319,483
----------------------------------------------------------------------------

Balance, January 1, 2014        $ 119,741,040    $ 1,039,705    $ 7,987,237

Net loss for the period                     -              -              -

Cumulative translation
 adjustment                                 -              -              -

----------------------------------------------------------------------------

Total comprehensive loss
 for the period                             -              -              -

Common shares, net of     8
 share issuance costs               9,470,403              -              -

Share based compensation  11                -              -        297,631
----------------------------------------------------------------------------
Balance as at June 30,
 2014                           $ 129,211,443    $ 1,039,705    $ 8,284,868
----------------------------------------------------------------------------


                                  Accumulated
                                        other
                                comprehensive
                          Notes  income (loss)       Deficit          Total
                               ---------------------------------------------

Balance, January 1, 2013            $ 362,920  $ (81,598,627)   $ 4,750,488

Net loss for the period                     -    (17,558,895)   (17,558,895)

Cumulative translation
 adjustment                        (1,530,274)             -     (1,530,274)

----------------------------------------------------------------------------

Total comprehensive loss
 for the period                    (1,530,274)   (17,558,895)   (19,089,169)

Common shares, net of
 share issuance costs                       -              -     41,526,379

Share based compensation                    -              -      1,000,556
----------------------------------------------------------------------------
Balance as at June 30,
 2013                            $ (1,167,354) $ (99,157,522)  $ 28,188,254
----------------------------------------------------------------------------

Balance, January 1, 2014         $ (1,639,862) $(113,553,555)  $ 13,574,565

Net loss for the period                     -    (10,038,716)   (10,038,716)

Cumulative translation
 adjustment                           100,199              -        100,199

----------------------------------------------------------------------------

Total comprehensive loss
 for the period                       100,199    (10,038,716)    (9,938,517)

Common shares, net of     8
 share issuance costs                       -              -      9,470,403

Share based compensation  11                -              -        297,631
----------------------------------------------------------------------------
Balance as at June 30,
 2014                            $ (1,539,663) $(123,592,271)  $ 13,404,082
----------------------------------------------------------------------------


                     TRIMEL PHARMACEUTICALS CORPORATION
           CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
              FOR THE SIX MONTHS ENDED JUNE 30, 2014 AND 2013
                                 UNAUDITED
                        (expressed in U.S. Dollars)

                                                        2014           2013
                                              ------------------------------

CASH FLOWS FROM OPERATING ACTIVITIES
----------------------------------------------
Net loss for the period                        $ (10,038,716) $ (17,558,895)
Items not requiring an outlay of cash:
  Adjustment for foreign exchange (gain)/loss        220,411       (175,959)
  Amortization of intangible assets                  147,900        147,900
  Depreciation of property and equipment           1,078,511        412,561
  Interest on long-term debt and other
   financing costs                                   356,498        658,378
  Change in fair value of derivative financial
   instrument                                         27,919       (146,914)
  Share based compensation                           297,631      1,000,556
  Impairment of property and equipment                45,138          9,338
Net changes in non-cash working capital items
 related to operating activities:
  Inventory                                         (813,763)             -
  Prepaids and other assets                         (116,582)    (1,926,000)
  Accounts payable and accrued liabilities        (4,579,699)       383,458
Provisions                                                 -        (41,620)
                                              ------------------------------
                                                 (13,374,752)   (17,237,197)
                                              ------------------------------

CASH FLOWS FROM FINANCING ACTIVITIES
----------------------------------------------
Proceeds from issuance of common shares, net
 of financing costs                                9,470,403     41,526,379
Financing costs, long-term debt                      (70,907)             -
Payment of long-term debt obligations             (1,500,000)    (1,250,000)
Payment of capital lease obligations                       -       (140,551)
Interest paid                                       (180,274)      (319,602)
                                              ------------------------------
                                                   7,719,222     39,816,226
                                              ------------------------------

CASH FLOWS FROM INVESTING ACTIVITIES
----------------------------------------------
Acquisition of property and equipment, net of
 deposits                                            (58,838)      (245,611)
Proceeds from sale of property and equipment               -          2,812
                                              ------------------------------
                                                     (58,838)      (242,799)
                                              ------------------------------


NET (DECREASE)/INCREASE IN CASH FOR THE PERIOD    (5,714,368)    22,336,230

Exchange (loss) on cash                             (107,085)    (1,238,830)

CASH BEGINNING OF PERIOD                          18,111,145      9,216,999
                                              ------------------------------

CASH END OF PERIOD                              $ 12,289,692   $ 30,314,399
                                              ------------------------------

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
Everywhere we turn in our industry we can find strong opinions about the direction, type and nature of cloud’s impact on computing and business. Another word that is used in every context in our industry is “hybrid.” In his session at 20th Cloud Expo, Alvaro Gonzalez, Director of Technical, Partner and Field Marketing at Peak 10, will use a combination of a few conceptual props and some research recently commissioned by Peak 10 to offer a real-world consideration of how the various categories of...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
SYS-CON Events announced today that Outscale, a global pure play Infrastructure as a Service provider and strategic partner of Dassault Systèmes, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2010, Outscale simplifies infrastructure complexities and boosts the business agility of its customers. Outscale delivers a secure, reliable and industrial strength solution for its customers, which in...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus intern...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
In order to meet the rapidly changing demands of today’s customers, companies are continually forced to redefine their business strategies in order to meet these needs, stay relevant and continue to see profitable growth. IoT deployment and development is integral in this transformation, and today businesses are increasingly seeing the value of investing their resources into IoT deployments. These technologies are able increase ROI through projects such as connecting supply chains or enabling sm...
Regardless of what business you’re in, it’s increasingly a software-driven business. Consumers’ rising expectations for connected digital and physical experiences are driving what some are calling the "Customer Experience Challenge.” In his session at @DevOpsSummit at 20th Cloud Expo, Marco Morales, Director of Global Solutions at CollabNet, will discuss how organizations are increasingly adopting a discipline of Value Stream Mapping to ensure that the software they are producing is poised to o...
This talk centers around how to automate best practices in a multi-/hybrid-cloud world based on our work with customers like GE, Discovery Communications and Fannie Mae. Today’s enterprises are reaping the benefits of cloud computing, but also discovering many risks and challenges. In the age of DevOps and the decentralization of IT, it’s easy to over-provision resources, forget that instances are running, or unintentionally expose vulnerabilities.
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.